Literature DB >> 18063343

Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.

Javier Rejas1, Julio Bobes, Celso Arango, Pedro Aranda, Rafael Carmena, Margarida Garcia-Garcia.   

Abstract

OBJECTIVE: To analyze the concordance between standard and modified NCEP-ATP-III criteria for identification of metabolic syndrome (MS) in outpatients with schizophrenia.
METHOD: We used the sample from a cross-sectional study carried out to ascertain the prevalence of MS in schizophrenia. Kappa agreement and the symmetry Kendall's tau-b coefficients were calculated in a post-hoc analysis, a long with McNemar test and logistic regression models.
RESULTS: The study enrolled 1,452 consecutive outpatients. MS was found in 24.6% (95%CI: 22.4%-26.8%) using the standard criteria and in 25.5% (23.2%-27.7%) using the modified criteria. Agreement was high; kappa 0.81 (p<0.0001) and tau-b 0.81 (p<0.0001), with a McNemar value of 0.2325. Kappa coefficients varied between 1.0 and 0.76 in subgroups according to sex, age-group, severity of disease, and duration of therapy.
CONCLUSIONS: MS in outpatients with schizophrenia may be assessed by either the standard or the modified NCEP ATP III criteria without losing reliability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063343     DOI: 10.1016/j.schres.2007.10.015

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis.

Authors:  Giuseppe Carrà; Francesco Bartoli; Daniele Carretta; Cristina Crocamo; Alberto Bozzetti; Massimo Clerici; Paul E Bebbington
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-22       Impact factor: 4.328

2.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

3.  The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Authors:  M K Yazici; A E Anil Yağcioğlu; A Ertuğrul; N Eni; S Karahan; E Karaağaoğlu; S L Tokgözoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-06-03       Impact factor: 5.270

4.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

5.  The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

6.  Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.

Authors:  Sameed Ahmed M Khatana; Joshua Kane; Tracey H Taveira; Mark S Bauer; Wen-Chih Wu
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

7.  Long-term prognostic value of macrophage migration inhibitory factor in ST-segment elevation myocardial infarction patients with metabolic syndrome after percutaneous coronary intervention.

Authors:  Xiao-Lin Yu; Qian Zhao; Fen Liu; Yu-Juan Yuan; Bin-Bin Fang; Xue-He Zhang; Wen-Ling Li; Xiao-Mei Li; Guo-Li Du; Xiao-Ming Gao; Yi-Ning Yang
Journal:  Front Cardiovasc Med       Date:  2022-08-11

Review 8.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.